Table 2 Comparison of clinical features in patients with MOG-IgG-positive isolated optic neuritis according to the disease course
Variables | CRION with MOG-IgG (n = 11) | Non-CRION with MOG-IgG (n = 11) | P value |
|---|---|---|---|
Age at 1st onset (years) | 41.4 ± 12.8 (20.8–62.1) | 45 ± 21 (15–70.7) | n.s. |
Sex (M:F) | 4:7 | 6:5 | n.s. |
Presence of the serum IgG1 MOG-IgG (n) | 11 (100%) | 11 (100%) | n.s. |
Relapsing disease course (n) | 11 (100%) | 0 | < 0.001 |
Duration of oral immunosuppressive treatment after 1st attack (months) | 1.0 ± 1.0 (0–2.8) | 2.4 ± 2.8 (0–9.1) | n.s. |
Unilateral:Bilateral involvement (n) | 6:5 | 6:5 | n.s. |
Pain with eye movement (n) | 9 (82%) | 8 (73%) | n.s. |
Optic disc swelling (n) | 3/9 (33%) | 7 (64%) | n.s. |
Visual acuity at nadir (logMAR) | 1.5 ± 0.9 (0–2.6) | 1.3 ± 1 (0–2.3) | n.s. |
Visual acuity less than 20/200 at nadir (n) | 8/10 (80%) | 5/10 (50%) | n.s. |
Enhancement of optic nerve on MRI (n) | 11 (100%) | 10/10 (100%) | n.s. |
Perineural enhancement of optic nerve on MRI (n) | 5/7 (71%) | 6/10 (60%) | n.s. |
Anatomical segment of optic nerve enhancement | |||
Proportion in orbital area (%) | 70.0 ± 26 (30–100) | 69.5 ± 30 (20–100) | n.s. |
Orbital (n) | 9/9 (100%) | 10/10 (100%) | n.s. |
Canalicular (n) | 3/9 (33%) | 4/10 (40%) | n.s. |
Intracranial (n) | 2/9 (22%) | 0/10 (0%) | n.s. |
Chiasmal (n) | 1/9 (11%) | 0/10 (0%) | n.s. |
Pattern of visual field defect at first attack (n) | |||
Central | 5 (45%) | 5 (46%) | n.s. |
Altitudinal | 1 (10%) | 3 (27%) | n.s. |
Diffuse | 5 (45%) | 3 (27%) | n.s. |
Total follow-up duration (months) | 45.7 ± 25.8 (5.8–104.5) | 42.6 ± 31.8 (9.1–95.8) | n.s. |
Total number of attacks (n) | 4.1 ± 1.8 (2–7) | 1 ± 0 (1–1) | < 0.001 |
Time interval between 1st and 2nd attack (months) | 2.3 ± 2.2 (0.4–7) | – | – |
Frequency (total number of attacks/years) | 1.7 ± 1.6 (0.3–6.2) | 0.6 ± 0.6 (0.1–2.1) | 0.023 |
Visual acuity at final follow-up (logMAR) | 0.2 ± 0.7 (−0.1–2.3) | 0 ± 0.1 (−0.2–0.2) | n.s. |
Visual acuity more than 20/40 at final follow-up | 10/11 (91%) | 9/9 (100%) | n.s. |
Retinal nerve fiber layer thickness (μm) | |||
Average | 65.7 ± 11.5 (50–81) | 83.3 ± 12.5 (69–92) | 0.040 |
Superior | 80.7 ± 21.1 (52–107) | 107.7 ± 24.9 (79–124) | n.s. |
Temporal | 43.7 ± 8.7 (33–55) | 60.3 ± 1.5 (59–62) | 0.001 |
Inferior | 81.5 ± 21.8 (51–114) | 99 ± 24.8 (71–118) | n.s. |
Nasal | 60.3 ± 9.0 (46–77) | 70 ± 7.8 (65–79) | n.s. |
Ganglion cell-inner plexiform layer thickness (μm) | |||
Average | 64.4 ± 6.5 (52–72) | 76 ± 5.6 (71–82) | 0.002 |
Minimum | 59.3 ± 7.0 (45–70) | 68.7 ± 9 (60–78) | 0.006 |
Central macular layer thickness (μm) | 242.5 ± 21.2 (215–282) | 237.3 ± 22.9 (207–248) | n.s. |